#United States #Anaheim #CovarsaDx #IVD Solutions #ADLM 2026

CovarsaDx® to Exhibit at ADLM 2026

CovarsaDx®, a leading contract research organization specializing in in vitro diagnostics (IVD) and medical devices, is gearing up for an impactful presence at the upcoming Association for Diagnostics Laboratory Medicine (ADLM) Annual Scientific Meeting. Scheduled for July 26-30, 2026, at the Anaheim Convention Center, this esteemed event will feature CovarsaDx's insights and expertise at Booth #1477.

The CovarsaDx team, including its new Senior Director of Regulatory Affairs, Lisa Baumhardt, will engage attendees and provide opportunities for private consultations. With over 30 years of experience in the medical device and IVD sectors, Lisa's expertise is expected to significantly contribute to the discussions surrounding regulatory strategies and compliance pathways required for successful product approvals.

Key Offerings at Booth #1477

At the booth, CovarsaDx will showcase its comprehensive approach to IVD and clinical research, encompassing essential areas such as:

• - Regulatory Strategy: Detailed discussions on navigating the complexities of regulatory pathways, including submissions for 510(k), De Novo, and PMA programs.
• - Study Design: Presentations on how to develop protocols aligned with submission requirements, ensuring thorough preparation for regulatory scrutiny.
• - Site Management and Enrollment: Insights into effective site management strategies that enhance participant recruitment and retention.
• - Data Management and Reporting: Demonstrations of CovarsaDx's submission-ready reporting capabilities designed to present data clearly and comprehensively.

In addition to these offerings, the team will highlight two of CovarsaDx's key resources:

• - SitePath™: A dedicated site operations function aimed at optimizing site and study management.
• - TrialPathDx™: CovarsaDx's proprietary Clinical Trial Management System designed to streamline trial processes and improve efficiency.

Industry Expertise on Display

Lisa Baumhardt, who has previously worked with renowned organizations such as GE Healthcare and Abbott Laboratories, will be sharing her extensive knowledge on the regulatory side of the healthcare industry. Her background combines experience from both the legal and practical perspectives of regulatory affairs, making her a valuable asset for CovarsaDx's sponsors.

Chermaen Lindberg, President and CEO of CovarsaDx, emphasized the importance of having such regulatory depth in their team: "Lisa's experience in IVDs and medical devices, along with her legal acumen, positions us uniquely to benefit the sponsors we work with. She offers insights that enhance our regulatory judgment and ultimately our partners' success."

Mark Boyle, Chief Operations Officer, also commented on the necessity of integrating clinical, regulatory, and quality strategies early in the process: "Successful regulatory submissions require more than just blind execution of studies; they require an intricate understanding of how all elements work together. We prioritize decisions made early on to execute studies effectively in the face of regulatory requirements."

Meeting slots are filling up rapidly as the event approaches. Attendees interested in scheduling dedicated time with the CovarsaDx team are encouraged to reach out as soon as possible to secure their spot. Walk-ins are also welcome at Booth #1477.

About CovarsaDx

CovarsaDx is a trailblazing Clinical Research Organization (CRO) that specializes in the development of in vitro diagnostics (IVDs) and medical devices. The organization is committed to providing tailored responses to the evolving needs of patient populations and regulatory landscapes, thereby facilitating faster pathways to market for innovative healthcare solutions. With a seasoned team skilled in regulatory, clinical, and quality operations, CovarsaDx is strategically positioned to generate robust evidence that advances technologies aimed at saving lives.